Listed

Pharming Group N.V.: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Apr 4, 2024 and accepted by EDGAR at Apr 4, 2024, 08:03 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31$245.3mifrs-full:RevenueFromContractsWithCustomers
Cost of revenue12 months2023-01-01 to 2023-12-31$25.2mifrs-full:CostOfSales
Gross profit12 months2023-01-01 to 2023-12-31$220.1mifrs-full:GrossProfit
Operating income12 months2023-01-01 to 2023-12-31−$5.4mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2023-01-01 to 2023-12-31−$1.5mifrs-full:IncomeTaxExpenseContinuingOperations
Diluted EPS12 months2023-01-01 to 2023-12-31−$0.02ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2023-01-01 to 2023-12-31−$0.02ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2023-01-01 to 2023-12-31−$17.3mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31$1.4mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2023-12-31$61.7mifrs-full:CashAndCashEquivalents
Current assetsAt period end2023-12-31$316.3mifrs-full:CurrentAssets
Total assetsAt period end2023-12-31$462.9mifrs-full:Assets
Current liabilitiesAt period end2023-12-31$78.0mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2023-12-31$218.8mifrs-full:Equity
Shares outstandingAt period end2023-12-31671,073,243 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001828316-24-000008. Last ingested by Listed: Nov 6, 2026, 11:08 ET. Listed shows no prices and gives no investment advice.